BioCentury
ARTICLE | Company News

FDA snubs Brinavess resubmission for AF

August 21, 2017 9:17 PM UTC

Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) said FDA informed the company that its proposed data package for IV Brinavess vernakalant to treat atrial fibrillation would not be sufficient to support resubmission of an NDA.

On Monday, Cardiome lost C$1.73 (35%) to C$3.26 in Toronto and fell $1.27 (33%) to $2.60 on NASDAQ...

BCIQ Company Profiles

Correvio Pharma Corp.